New criteria related to prodromal Alzheimer’s disease (AD) have been proposed to overcome the issue of heterogeneity of patients with mild cognitive impairment (MCI) and to better define patients in early stage AD. Only few therapeutic trials, if any, have been reported using this newly defined population. The objective of this study was to assess […]
Background: Prevention strategies are urgently needed to tackle the growing burden of Alzheimer’s disease. We aimed to assess efficacy of long-term use of standardised ginkgo biloba extract for the reduction of incidence of Alzheimer’s disease in elderly adults with memory complaints.; Methods: In the randomised, parallel-group, double-blind, placebo-controlled GuidAge clinical trial, we enrolled adults aged […]
Objective: The Relevant Outcome Scale for Alzheimer’s disease (ROSA) is a novel, valid, and reliable instrument for multidimensional assessment of Alzheimer’s disease (AD) symptoms across all severity stages. The ROSA and four standard instruments — the Alzheimer’s disease Assessment Scale-cognitive (ADAS-cog), Severe Impairment Battery (SIB), Disability Assessment for Dementia (DAD), and the Neuropsychiatric Inventory (NPI) […]